What are the signs and symptoms of monkeypox, when should it be suspected, and how should it be evaluated and managed?

Mpox (Monkeypox): When to Suspect, How to Diagnose, and What to Do

Bold action now: suspect mpox in any patient with a new acute vesiculopustular or ulcerative rash (especially anogenital/oral), lymphadenopathy, and relevant exposure—immediately isolate, obtain lesion PCR, and begin supportive care; escalate to antivirals (e.g., tecovirimat) for severe disease or high-risk hosts to reduce morbidity, mortality, and preserve quality of life. 1, 2, 3

When to Suspect Mpox

• Core clinical triggers
  • Painful or pruritic rash evolving through macular → papular → vesicular → pustular → crusting stages over ~2–3 weeks; may be umbilicated; mucosal lesions common (oral, genital, anorectal) 2.
  • Tender lymphadenopathy (cervical, inguinal) with fever, chills, headache, myalgias, backache, fatigue; incubation 5–21 days 4, 2.
• High-risk settings/exposures
  • Close skin-to-skin or sexual contact with a case; outbreaks disproportionately affect men who have sex with men, but all contacts at risk 3, 5.
  • Contact with contaminated materials (bedding, clothing), respiratory secretions, or lesions 2, 3.
  • Animal exposure (particularly rodents/exotic pets) in outbreak contexts 6, 7, 8.
• Red flags for severe disease (prompt antiviral consideration/admission)
  • Immunocompromise (e.g., advanced HIV), pregnancy, children; complications: encephalitis, pneumonia, severe mucosal/oropharyngeal disease threatening airway, sepsis, extensive ocular disease 1, 2, 9.

Differential Diagnosis Pitfalls (don’t miss)

• Varicella/zoster, HSV, secondary syphilis, bacterial folliculitis, scabies with impetigo, hand-foot-mouth, molluscum; arboviruses if febrile rash; smallpox not circulating but orthopox morphology overlaps—history and PCR distinguish 2.
• Mixed STIs may co-occur; test appropriately 1.

Immediate Infection Control (to protect patients and contacts)

• Isolate patient: single room, cover lesions; avoid close contact/fomites; use standard/contact/airborne precautions per CDC orthopox guidance; counsel no sex/skin-to-skin until all lesions crust, scab, and re-epithelialize 1, 3.
• Notify public health for testing access, contact tracing, and vaccine prophylaxis pathways 1, 3.

Diagnostic Algorithm (maximize accuracy, speed)

• Test of choice (gold standard): lesion-based PCR for MPXV
  • Collect from multiple lesions (preferably different sites/stages), vigorously swab base or unroof crusts; place in appropriate media; avoid blood-only testing (lower yield) 4, 2.
• Additional studies (as indicated by severity/complications)
  • CBC, CMP; HIV test if status unknown; imaging for pneumonia; ophthalmology for ocular lesions; LP if encephalitis suspected 1, 2.
• Do not delay isolation/supportive care while awaiting results 1.

Management: Stepwise, outcome-focused

1. Supportive care for all (foundation; reduces complications)

   • Pain control (NSAIDs/acetaminophen; opioids if severe); aggressive topical/oral analgesia for mucosal/anogenital disease.
   • Hydration, nutrition; bowel regimen; wound care: keep lesions clean/dry; saline soaks; treat superinfection (target staph/strep if cellulitis) 1, 2.
   • Pruritus control (antihistamines/topicals).
   • Ocular involvement: urgent ophthalmology; avoid topical steroids unless advised; consider antivirals due to vision risk 2.

2. Antiviral therapy (use when risk of poor outcomes is significant)

   • Indications (choose therapy promptly to preserve QOL, prevent severe morbidity/mortality):
     • Severe disease (extensive cutaneous, hemorrhagic/necrotic lesions, airway risk, severe pain), progressive disease, hospitalization.
     • High-risk hosts: immunocompromised (e.g., low CD4 counts), pregnant, pediatric, or severe mucosal/ocular/proctitis involvement 1, 2, 9.
   • Options (off-label for mpox; supported by smallpox/orthopox data):
     • First-line: tecovirimat (TPOXX) via public health access; favored for tolerability and orthopox activity 1.
     • Alternatives/adjuncts if progression or contraindications: brincidofovir or cidofovir; weigh renal/hepatic risks; consider infectious diseases consultation 1.
   • Monitor for response; manage adverse effects; escalate care if deteriorating.

3. Complication-specific care

   • Proctitis/anorectal pain: multimodal analgesia; stool softeners; rule out STI coinfections and treat.
   • Airway compromise from oropharyngeal edema: early ENT/airway team; ICU if needed; case evidence of fatal course in advanced HIV underscores urgency 9.
   • Encephalitis/pneumonia/sepsis: hospitalize; supportive critical care; antiviral therapy; broad diagnostics 1, 2.

4. Postexposure prophylaxis (PEP) and prevention to protect contacts

   • Vaccination for high-risk exposures/populations (public health programs): non-replicating JYNNEOS preferred over replicating ACAM2000 due to safety; consider within 4–14 days postexposure to reduce disease severity and improve QOL 1.
   • Educate on reducing skin-to-skin contact during outbreaks; avoid sharing linens/clothing; proper disinfection 3.

Follow-up and Return-to-Community Criteria

• De-isolation when all lesions crusted, scabs fallen off, and new intact skin formed; counsel on scarring risk and secondary infection prevention 1, 2.
• Assess pain control, hydration, mental health/QOL; screen/treat STI coinfections; ensure HIV linkage if positive 1, 3.

Evidence Notes and Caveats

• Highest-quality, recent clinical guidance emphasizes isolation, lesion PCR diagnosis, supportive care for all, and targeted antivirals for severe/high-risk cases; no FDA-approved mpox-specific therapy—use orthopox antivirals off-label with public health oversight 1.
• Older public-animal contact guidelines document zoonotic transmissions (including prairie dog–linked cases) and underscore exposure risks; useful for suspicion with animal contact but not for modern clinical management nuances 6, 7, 8.
• Vaccinia/smallpox ACIP documents inform orthopox biology and vaccine context but do not replace current mpox-specific vaccine preferences (JYNNEOS favored for safety) 10.

Common Pitfalls (and how to avoid them)

• Missing mpox in patients with isolated anogenital/oral ulcers or rectal pain—always examine skin/mucosa thoroughly and test lesions 2, 3.
• Delayed isolation/testing—initiate both at first suspicion to reduce transmission and complications 1, 3.
• Undertreating severe pain/mucosal disease—optimize analgesia early; consider antivirals in severe/high-risk to prevent disability and hospitalization 1, 2.
• Overreliance on blood PCR—collect from multiple lesions for highest sensitivity 4, 2.
• Ignoring HIV status—test and manage; advanced HIV is linked to severe/fatal courses 9, 1.